Litcius/Paper detail

Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors

Sally C. M. Lau, Aline Fusco Fares, Lisa W. Le, Kate M. Mackay, Spencer Soberano, Sze Wah Samuel Chan, Elliot Smith, Malcolm Ryan, Ming‐Sound Tsao, Penelope A. Bradbury, Prodipto Pal, Frances A. Shepherd, Geoffrey Liu, Natasha B. Leighl, Adrian G. Sacher

2021Clinical Lung Cancer65 citationsDOI

Topics & Concepts

MedicineHazard ratioLung cancerInternal medicineOncologyExonConfidence intervalResponse Evaluation Criteria in Solid TumorsCancer researchMutationPopulationProgressive diseaseChemotherapyBiologyGeneticsGeneEnvironmental healthCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies
Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors | Litcius